Total medical devices industry artificial intelligence venture financing deals worth $1.9bn were announced globally in Q2 2021, led by $600m venture financing of CMR Surgical, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 70.9% over the previous quarter and a rise of 97.6% when compared with the last four-quarter average, which stood at $951.62m.
Comparing artificial intelligence deals value in different regions of the globe, North America held the top position, with total announced deals worth $986.43m in the period. At the country level, the US topped the list in terms of deal value at $986.43m.
In terms of volumes, North America emerged as the top region for medical devices industry artificial intelligence venture financing deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of artificial intelligence venture financing deals activity in Q2 2021 was the US with 21 deals, followed by the UK with three and Germany with two.
In 2021, at the end of , artificial intelligence venture financing deals worth $1.9bn were announced globally in medical devices industry, marking an increase of 110.6% year on year.
Artificial Intelligence venture financing deals in medical devices industry in Q2 2021: Top deals
The top five artificial intelligence venture financing deals in medical devices industry accounted for 67.1% of the overall value during Q2 2021.
The combined value of the top five artificial intelligence venture financing deals stood at $1.26bn, against the overall value of $1.9bn recorded for the quarter.
The top five medical devices industry artificial intelligence venture financing deals of Q2 2021 tracked by GlobalData were:
1) Ally Bridge Group, Cambridge Innovation Capital, Chimera Partners, GE Healthcare, LGT Impact Ventures, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund II, Tencent Holdings and Watrium’s $600m venture financing of CMR Surgical
2) The $255m venture financing of InSilico Medicine by B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus
3) 8VC , Adage Capital Partners, Biospring Partners, Bristol-Myers Squibb, D1 Capital Partners, General Atlantic, General Catalyst Partners, Kaiser Permanente Ventures, KdT Ventures, LabCorp Venture Fund, Merck Global Health Innovation Fund, Polaris Partners, Refactor Capital and Tiger Global Management’s $165m venture financing of PathAI
4) The $130m venture financing of Huma Therapeutics by HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures
5) AME Cloud Ventures, Ardea Partners, Aspect Ventures, AXA Venture Partners, Canvas Ventures, Centene, General Atlantic, NGP Capital and Workday Ventures’ venture financing of Vida Health for $110m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.